News
GeneDx beat Q2 estimates, raised guidance, and is seeing rapid test volume growth and stronger reimbursements. Check out why ...
The most assertive raise of the three came from BTIG's Mark Massaro, who now feels GeneDx is worth $125 per share, well up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback